Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for...